Literature DB >> 21742835

Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity.

Marc Brisson1, Nicolas van de Velde, Eduardo L Franco, Mélanie Drolet, Marie-Claude Boily.   

Abstract

Our aim was to examine the potential incremental impact of vaccinating boys against human papillomavirus (HPV) on vaccine-type infection in females and males, using an individual-based HPV transmission-dynamic model. Under base assumptions (vaccine efficacy = 99%, duration of protection = 20 years, coverage = 70%), vaccinating 12-year-old boys, in addition to girls, resulted in an incremental reduction in HPV-16/18 (HPV-6/11) incidence over 70 years of 16% (3%) in females and 23% (4%) in males. The benefit of vaccinating boys decreased with improved vaccination coverage in girls. Given the important predicted herd immunity impact of vaccinating girls under moderate to high vaccine coverage, the potential incremental gains of vaccinating boys are limited.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21742835     DOI： 10.1093/infdis/jir285

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  46 in total

1.  The road ahead for cervical cancer prevention and control.

Authors:  J E Tota; A V Ramana-Kumar; Z El-Khatib; E L Franco
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

2.  Vaccination against human papilloma virus infection in male adolescents: knowledge, attitudes, and acceptability among parents in Italy.

Authors:  Aida Bianco; Claudia Pileggi; Francesca Iozzo; Carmelo Giuseppe A Nobile; Maria Pavia
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

Review 3.  Health policy: HPV vaccination in boys - will the UK join the fight?

Authors:  Liam Masterson; Matt Lechner
Journal:  Nat Rev Clin Oncol       Date:  2016-11-18       Impact factor: 66.675

Review 4.  Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.

Authors:  Mohamed-Béchir Ben Hadj Yahia; Anaïs Jouin-Bortolotti; Benoît Dervaux
Journal:  Clin Drug Investig       Date:  2015-08       Impact factor: 2.859

5.  Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies.

Authors:  Marc D Ryser; Kevin McGoff; David P Herzog; David J Sivakoff; Evan R Myers
Journal:  Epidemics       Date:  2015-02-07       Impact factor: 4.396

Review 6.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

7.  Revisiting assumptions about age-based mixing representations in mathematical models of sexually transmitted infections.

Authors:  C W Easterly; F Alarid-Escudero; E A Enns; S Kulasingam
Journal:  Vaccine       Date:  2018-08-06       Impact factor: 3.641

Review 8.  Reducing HPV-associated cancer globally.

Authors:  Douglas R Lowy; John T Schiller
Journal:  Cancer Prev Res (Phila)       Date:  2012-01

9.  HPV vaccination and cervical cancer.

Authors:  Anne Szarewski
Journal:  Curr Oncol Rep       Date:  2012-12       Impact factor: 5.075

10.  Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine.

Authors:  Eric Adjei Boakye; Betelihem B Tobo; Rebecca P Rojek; Kahee A Mohammed; Christian J Geneus; Nosayaba Osazuwa-Peters
Journal:  Hum Vaccin Immunother       Date:  2017-08-30       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.